Today's Daily Dose brings you news about the acquisition of Momenta by J&J, FDA refusing to approve BioMarin's hemophilia gene therapy, ThermoGenesis' COVID-19 combo kit getting red-flagged, Merck's Keytruda KEYNOTE-590 study meeting trial goals, the anticipated milestones of NuCana, and Turning Point's TRIDENT-1 study data.
from RTT - Biotech https://ift.tt/2QbBigM
via IFTTT
No comments:
Post a Comment